← Back to Screener
HCW Biologics Inc. Common Stock (HCWB)
Price$0.42
Favorite Metrics
Price vs S&P 500 (26W)-95.65%
Price vs S&P 500 (4W)-61.77%
Market Capitalization$2.74M
All Metrics
Book Value / Share (Quarterly)$0.84
P/TBV (Annual)1.11x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-79.94%
Cash Flow / Share (Quarterly)$-4.08
Price vs S&P 500 (YTD)-60.73%
Gross Margin (TTM)19.99%
Net Profit Margin (TTM)-3601.01%
EPS (TTM)$-4.85
10-Day Avg Trading Volume0.62M
EPS Excl Extra (TTM)$-4.85
Revenue Growth (5Y)-57.90%
EPS (Annual)$-3.79
ROI (Annual)-83.14%
Gross Margin (Annual)19.99%
Net Profit Margin (5Y Avg)-3418.02%
Cash / Share (Quarterly)$0.60
Revenue Growth QoQ (YoY)-93.16%
ROA (Last FY)-32.46%
Revenue Growth TTM (YoY)-98.69%
EBITD / Share (TTM)$-2.97
ROE (5Y Avg)-115.76%
Operating Margin (TTM)-7344.64%
Cash Flow / Share (Annual)$-4.08
P/B Ratio0.99x
P/B Ratio (Quarterly)0.95x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)226.39x
Net Interest Coverage (TTM)-4.76x
ROA (TTM)-30.28%
EPS Incl Extra (Annual)$-3.79
Current Ratio (Annual)0.11x
Quick Ratio (Quarterly)0.10x
3-Month Avg Trading Volume5.70M
52-Week Price Return-95.09%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.66
P/S Ratio (Annual)50.54x
Asset Turnover (Annual)0.00x
52-Week High$17.80
Operating Margin (5Y Avg)-3324.26%
EPS Excl Extra (Annual)$-3.79
CapEx CAGR (5Y)-29.10%
26-Week Price Return-91.66%
Quick Ratio (Annual)0.10x
13-Week Price Return-66.64%
Total Debt / Equity (Annual)2.46x
Current Ratio (Quarterly)0.11x
Enterprise Value$7.598
Revenue / Share Growth (5Y)-25.78%
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-14677.69%
Cash / Share (Annual)$0.60
3-Month Return Std Dev217.15%
Net Income / Employee (TTM)$-0
EBITDA Interim CAGR (5Y)0.07%
ROE (Last FY)-287.90%
Net Interest Coverage (Annual)-1.09x
EPS Basic Excl Extra (Annual)$-3.79
Receivables Turnover (TTM)0.11x
Total Debt / Equity (Quarterly)2.46x
EPS Incl Extra (TTM)$-4.85
Receivables Turnover (Annual)0.18x
ROI (TTM)7.51%
P/S Ratio (TTM)81.67x
Pretax Margin (5Y Avg)-3418.02%
Revenue / Share (Annual)$0.03
Tangible BV / Share (Annual)$1.04
Price vs S&P 500 (52W)-124.92%
Year-to-Date Return-58.08%
5-Day Price Return20.66%
EPS Normalized (Annual)$-3.79
ROA (5Y Avg)-55.06%
Net Profit Margin (Annual)-14677.69%
Month-to-Date Return13.06%
Cash Flow / Share (TTM)$-0.52
EBITD / Share (Annual)$-3.02
Operating Margin (Annual)-14201.49%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-61.80%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-4.85
P/TBV (Quarterly)1.75x
P/B Ratio (Annual)0.95x
Pretax Margin (TTM)-3601.01%
Book Value / Share (Annual)$0.84
Price vs S&P 500 (13W)-67.33%
Beta1.00x
Revenue / Share (TTM)$0.01
ROE (TTM)26.01%
52-Week Low$0.25
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
HCWBHCW Biologics Inc. Common Stock | 81.67x | -98.69% | 19.99% | — | $0.42 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
HCW Biologics is a clinical-stage biopharmaceutical company developing immunotherapies to treat age-related diseases by targeting chronic inflammation. The company uses its proprietary TOBI discovery platform to generate two lead candidates: HCW9218, which neutralizes growth factors and stimulates immune cells, and HCW9302, which activates regulatory T cells to reduce inflammation. This approach targets the inflammation-aging link to potentially extend healthspan across multiple indications.